Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170937
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2005-09-10
Brief Title:
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan 320 mg and Hydrochlorothiazide 25 mg Combined and Alone in Patients With Metabolic Syndrome
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone in Patients With Metabolic Syndrome
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity hypertension elevated blood lipids and sugar Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases The purpose of this study is to determine whether two common drugs to lower blood pressure whether used separately or in combination have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None